NCT04194892View on ClinicalTrials.gov

A Crossover Study to Evaluate Pegilodecakin (LY3500518) in Healthy Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

12

Participants

Timeline

Start Date

January 19, 2018

Primary Completion Date

March 14, 2018

Study Completion Date

March 14, 2018

Conditions

Healthy

Interventions

BIOLOGICAL

Pegilodecakin

Administered SQ

Trial Locations (1)

78744

PPD Phase 1 Clinic, Austin

Sponsors

Collaborators (1)

ARMO BioSciences

All Listed Sponsors

collaborator

ARMO BioSciences

INDUSTRY

lead

Eli Lilly and Company

INDUSTRY

NCT04194892 - A Crossover Study to Evaluate Pegilodecakin (LY3500518) in Healthy Participants | Biotech Hunter | Biotech Hunter